An approved medicine has been associated with post-marketing adverse event case reports following administration of the drug in the eye. Novartis is seeking plausible hypotheses for these observations based upon publicly available information.
Novartis is launching this Ideation Challenge for a recently introduced drug in the market that is linked with post-marketing adverse event case reports following administration of the drug in the human eye. A small number of patients experienced adverse events termed as “retinal vasculitis” and/or “retinal vascular occlusion” that may result in severe vision loss and/or decreased visual acuity. Typically, these events occurred in the presence of intraocular inflammation (IOI). This is a brainstorming activity to help examine the potential root cause of these reported post-marketing adverse events with a particular interest in identifying parallels from life or physical sciences to provide relevant and plausible insights as to why these rare reported post-marketing adverse events have occurred.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on September 20, 2020.
About the Seeker
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.